PYC 003
Alternative Names: PYC-003Latest Information Update: 15 Nov 2023
At a glance
- Originator PYC Therapeutics
- Class Antisense oligonucleotides; Drug conjugates; Morpholines; Peptide drug conjugates
- Mechanism of Action RNA interference; SHANK3 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Polycystic kidney disease; Telomeric 22q13 Monosomy Syndrome
Most Recent Events
- 13 Nov 2023 Preclinical trials in Polycystic kidney disease in Australia(unspecified route), prior to November 2023
- 13 Nov 2023 PYC Therapeutics plans to file an IND application with the US FDA in USA for Polycystic kidney disease (PKD), in H2 2024
- 20 Oct 2022 Preclinical trials in Telomeric 22q13 Monosomy Syndrome in Australia (Intracerebral) (PYC Therapeutics pipeline; October 2022)